Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2014

Planlagt Fastgjort Låst Flyttet Genmab
2.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • W Offline
    W Offline
    wermuth
    wrote on sidst redigeret af
    #101

    Carnegie på banen, længe siden vi har set dem

    1 Reply Last reply
    0
    • J Offline
      J Offline
      JKY_VH
      wrote on sidst redigeret af
      #102

      jep, det plejer at være et godt tegn

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #103

        Roche Hldg member, Ventana, signs companion diagnostic agreement with
        international biotech for antibody drug conjugate program (37.25
        +0.03)

        Ventana Medical Systems, a member of the Roche Group, announced that
        it has entered into an agreement with Genmab A/S, Copenhagen, Denmark
        for the development of companion diagnostic tools for Genmab's
        HuMax-TF-ADC antibody drug conjugate program.

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #104

          As part of the
          agreement, Ventana will provide its expertise and services towards the
          development of an immunohistochemistry companion diagnostic test for
          the detection of tissue factor in patient tumor samples. The TF assay
          will be developed for possible designation as the screening test in
          clinical trials involving HuMax-TF-ADC.

          Read more: http://www.briefing.com/Platinum/InDepth/InPlay.htm#ixzz2xpmqLlU7

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #105

            favicon

            (www.mygtn.tv)

            1 Reply Last reply
            0
            • J Offline
              J Offline
              JKY_VH
              wrote on sidst redigeret af
              #106

              Tak Solsen

              1 Reply Last reply
              0
              • investor1989I Offline
                investor1989I Offline
                investor1989
                wrote on sidst redigeret af
                #107

                Sukker btw. din arbejdskollega plextoren hvad laver han for tiden? lang tid siden vi har set ham

                1 Reply Last reply
                0
                • investor1989I Offline
                  investor1989I Offline
                  investor1989
                  wrote on sidst redigeret af
                  #108

                  spændende spændende solsen

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #109

                    En vigtig parameter, hvis man kan screene og give "sikkerhed" for effekt !

                    1 Reply Last reply
                    0
                    • investor1989I Offline
                      investor1989I Offline
                      investor1989
                      wrote on sidst redigeret af
                      #110

                      jep og det kan jo løfte effekten af Humax.TF-ADC når man laver randomiserede forsøg hvis man screener inden sådan at man kun får perosner ind som man ved responderer

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #111

                        Vi kan vel ikke forvente late breaking abstract fra Genmab i morgen på Humax TF ADC til AACR

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #112

                          Var det ikke ASCO Winkel lovede den til ?

                          1 Reply Last reply
                          0
                          • investor1989I Offline
                            investor1989I Offline
                            investor1989
                            wrote on sidst redigeret af
                            #113

                            Humax-TF-ADC på ASCO ? er du sindsyg. Rachel sagde til mig vi skulle være heldige hvis vi skulle se data på ASH

                            1 Reply Last reply
                            0
                            • investor1989I Offline
                              investor1989I Offline
                              investor1989
                              wrote on sidst redigeret af
                              #114

                              de har vel kun behandlet patienter i de meget meget lave dosis pt. ? de starter jo i de meget lavea dosis pga. giftigheden. så tror ASH er mere sandsynlig da vi så har nogle data fra lidt højere dosis og forhåbentlig nogle responser

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #115

                                Novod skriver om AACR som den første conf. der kan løfte Genmab højere. Men nævner ikke hvorfor !

                                1 Reply Last reply
                                0
                                • SolsenS Offline
                                  SolsenS Offline
                                  Solsen
                                  wrote on sidst redigeret af
                                  #116

                                  Biotech ned 2,7% http://finance.yahoo.com/q;_ylt=AuI8L3b6QbOJ1DBWdImi.44nv7gF;_ylc=X1MDMjE0MjQ3ODk0OARfcgMyBGZyA3VoM19maW5hbmNlX3dlYl9ncwRmcjIDc2EtZ3AEZ3ByaWQDBG5fZ3BzAzEwBG9yaWdpbgNmaW5hbmNlLnlhaG9vLmNvbQRwb3MDNARwcXN0cgMEcXVlcnkDXk5CSSwEc2FjAzEEc2FvAzE-?p=http%3A%2F%2Ffinance.yahoo.com%2Fq%3Fs%3D^NBI%26ql%3D0&type=2button&fr=uh3_finance_web_gs&uhb=uhb2&s=^NBI

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #117

                                    Tak for Ventana link. Gode nye tiltag fra Genmab for tiden

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      gentogen
                                      wrote on sidst redigeret af
                                      #118

                                      DDT01-03: Discovery and preclinical pharmacology of JNJ-61186372: A novel bispecific antibody targeting EGFR and cMET
                                      Sunday, Apr 06, 2014, 2:00 PM - 2:25 PM

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        gentogen
                                        wrote on sidst redigeret af
                                        #119

                                        Altså på AACR

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          gentogen
                                          wrote on sidst redigeret af
                                          #120

                                          Importantly, JNJ-61186372 effectively inhibited tumor growth in models with mutant EGFR and cMet activation, whereas single agent EGFR inhibitors were less effective. The preclinical data support the clinical development of JNJ-61186372 in patients with lung cancer and other malignancies associated with aberrant EGFR and cMET signaling.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger